Liu 2013.

Methods	Method of randomisation not clear.
Participants	People (age nm, sex nm) with acute nonlymphocytic leukaemia (stage nm) treated with daunorubicin (cumulative dose nm; peak dose (i.e. maximal dose received in 1 week) nm; infusion duration nm). Prior anthracycline therapy nm. Prior cardiac radiotherapy nm. Prior cardiac dysfunction nm.
Interventions	Dexrazoxane (ratio to anthracycline nm; timing in relation to anthracycline nm) (N = 20) versus no cardioprotective intervention (N = 22).
Outcomes	Heart failure (i.e. different abnormalities on echocardiography); in the abstract no clear dichotomous results were provided.
Notes	Unclear if this is an ongoing or completed study. Length of follow‐up nm. Cumulative anthracycline dose per treatment group nm. Age per treatment group nm.